MediWound (MDWD) Stock Price, News & Analysis

Company Overview

MediWound Ltd. (NASDAQ: MDWD) is a commercial‐stage biopharmaceutical company focused on the research, development and commercialization of novel therapeutic solutions for tissue repair and regeneration. Headquartered in Ra’anana, Israel, with commercial operations in the United States and Europe, the company was founded in 2002 and has since leveraged its expertise in human extracellular matrix and enzymatic technologies to address significant unmet medical needs in acute and chronic wounds.

The company’s lead product, NexoBrid®, is an enzyme‐based debriding agent approved in Europe and the United States for the removal of dead tissue (eschar) in adults with severe thermal burn injuries. NexoBrid® utilizes a proprietary concentrate of proteolytic enzymes to selectively dissolve necrotic tissue while preserving viable tissue, reducing the need for surgical intervention and improving healing outcomes. MediWound also markets Bridematrix®, a dermal regeneration template, in partnership with Tepha, Inc., and is advancing a pipeline of novel formulations designed to enhance wound healing and reduce scarring.

In addition to its burn care franchise, MediWound is exploring next‐generation extracellular matrix therapies for indications such as chronic non‐healing wounds and post‐surgical fibrosis. The company maintains manufacturing capabilities in Israel and has established strategic partnerships to support global distribution, including collaborations in Asia and Latin America. MediWound’s regulatory achievements include approvals in over 60 countries, reflecting a broad geographic footprint and a well‐developed commercial infrastructure.

The executive leadership team is headed by President and Chief Executive Officer Ariel Harel, whose two decades of experience in biotechnology and medical devices have guided MediWound’s transition from development to commercialization. The company’s senior management also includes seasoned experts in clinical development, regulatory affairs and global marketing, all of whom work under the oversight of an independent board of directors with deep expertise in life sciences. MediWound continues to invest in research and strategic partnerships, aiming to expand its portfolio and bring innovative wound care solutions to patients worldwide.

Key Stats

• Today's Range: $19.20 to $19.47
• 50-Day Range: $17.25 to $22.24
• 52-Week Range: $14.14 to $22.51
• Volume: 10,185 shs
• Average Volume: 71,329 shs
• Market Capitalization: $210.47 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $31.80
• Consensus Rating: Buy

MediWound Stock Analysis - MarketRank™

MediWound scored higher than 26% of companies evaluated by MarketBeat, and ranked 802nd out of 922 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

MediWound has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

MediWound has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for MediWound are expected to grow in the coming year, from ($2.66) to ($2.24) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of MediWound is -9.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of MediWound is -9.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

MediWound has a P/B Ratio of 6.74. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

12.32% of the float of MediWound has been sold short.

Short Interest Ratio / Days to Cover

MediWound has a short interest ratio ("days to cover") of 13, which indicates bearish sentiment.

Change versus previous month

Short interest in MediWound has recently decreased by 3.91%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

MediWound does not currently pay a dividend.

Dividend Growth

MediWound does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

12.32% of the float of MediWound has been sold short.

Short Interest Ratio / Days to Cover

MediWound has a short interest ratio ("days to cover") of 13, which indicates bearish sentiment.

Change versus previous month

Short interest in MediWound has recently decreased by 3.91%, indicating that investor sentiment is improving.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for MediWound this week, compared to 2 articles on an average week.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, MediWound insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 9.20% of the stock of MediWound is held by insiders.

Percentage Held by Institutions

46.83% of the stock of MediWound is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

MDWD Stock Analysis - Frequently Asked Questions

How have MDWD shares performed this year?

MediWound's stock was trading at $17.80 at the beginning of 2025. Since then, MDWD stock has increased by 9.4% and is now trading at $19.47.

How were MediWound's earnings last quarter?

MediWound Ltd. (NASDAQ:MDWD) posted its quarterly earnings data on Wednesday, May, 21st. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, topping analysts' consensus estimates of ($0.65) by $0.58. The biopharmaceutical company earned $3.96 million during the quarter, compared to analysts' expectations of $5.20 million. MediWound had a negative trailing twelve-month return on equity of 74.12% and a negative net margin of 110.45%.
Read the conference call transcript.

When did MediWound's stock split?

MediWound's stock reverse split on the morning of Tuesday, December 20th 2022.The 1-7 reverse split was announced on Tuesday, December 20th 2022. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, December 20th 2022. An investor that had 100 shares of stock prior to the reverse split would have 14 shares after the split.

How do I buy shares of MediWound?

Shares of MDWD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of MediWound own?

Based on aggregate information from My MarketBeat watchlists, some other companies that MediWound investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Adobe (ADBE), ServiceNow (NOW) and Palo Alto Networks (PANW).

Company Calendar

• Last Earnings: 5/21/2025
• Today: 7/06/2025
• Next Earnings (Estimated): 8/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:MDWD
• CIK: 1593984
• Web: www.mediwound.com
• Phone: 972779714100
• Fax: 972-77-971-4111
• Employees: 80
• Year Founded: 2001

Price Target and Rating

• Average Stock Price Target: $31.80
• High Stock Price Target: $39.00
• Low Stock Price Target: $25.00
• Potential Upside/Downside: +63.3%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.09)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$30.22 million
• Net Margins: -110.45%
• Pretax Margin: -110.23%
• Return on Equity: -74.12%
• Return on Assets: -30.92%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.15
• Quick Ratio: 1.99

Sales & Book Value

• Annual Sales: $20.22 million
• Price / Sales: 10.41
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.89 per share
• Price / Book: 6.74

Miscellaneous

• Outstanding Shares: 10,810,000
• Free Float: 9,814,000
• Market Cap: $210.47 million
• Optionable: Optionable
• Beta: 0.32